ArticleAging cell2026
Metabolic Profiling of Epigenetic Aging and Its Associations With Aging-Related Phenotypes and Modifiable Lifestyle Factors.
Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Epigenetic aging biomarkers are well-established hallmarks of biological aging, yet their metabolic underpinnings remain largely unexplored. Here, we characterized metabolic signatures associated with five epigenetic aging biomarkers (HorvathAge, HannumAge, DNAmPhenoAge, DunedinPACE, and DNAmTL) and examined their clinical relevance and potential determinants in 7162 Chinese older adults from two cohorts (primary and validation). We observed both shared and distinct metabolic associations across epigenetic aging biomarkers. Metabolic signatures of epigenetic aging biomarkers were derived using elastic net regression, showing moderate correlations with the corresponding epigenetic aging biomarkers (r = 0.21-0.36 in internal testing set, p < 0.05), with external replication further validating metabolic signatures of DNAmPhenoAge, DunedinPACE, and DNAmTL (r = 0.18-0.29, p < 0.05). These five metabolic signatures of epigenetic age acceleration (EAA) exhibited 279 significant associations with aging-related phenotypes including higher disease risk, poorer health status, and adverse clinical indicators. Gallstones, chronic kidney disease, and hepatitis, along with renal-, hepatic- and metabolic-related clinical indicators, were consistently associated with multiple metabolic signatures of EAA. Smoking status, alcohol consumption, body mass index (BMI), and physical activity were identified as modifiable lifestyle factors associated with metabolic signatures of EAA, with BMI showing the most consistent associations. Metabolic signatures of DunedinPACE and DNAmPhenoAA exhibited the most extensive associations with aging-related phenotypes and modifiable lifestyle factors in both primary and validation cohorts. These findings provide novel insights into the metabolic correlates of epigenetic aging biomarkers and underscore the potential of metabolomics-informed metrics of epigenetic aging as informative indicators of physiological decline and lifestyle effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.